Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.

The Journal of pathology - 1 Dec 2013

Tothill Richard W, Li Jason, Mileshkin Linda, Doig Ken, Siganakis Terence, Cowin Prue, Fellowes Andrew, Semple Timothy, Fox Stephen, Byron Keith, Kowalczyk Adam, Thomas David, Schofield Penelope, Bowtell David D

Abstract excerpt

The clinical management of patients with cancer of unknown primary (CUP) is hampered by the absence of a definitive site of origin. We explored the utility of massively-parallel (next-generation) sequencing for the diagnosis of a primary site of origin and for the identification of novel treatment options. DNA enrichment by hybridization capture of 701 genes of clinical and/or biological importance, followed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Copy Number Variations
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Evidence-Based Medicine

Share to Gene Expression Profiling

Share to Genes, Neoplasm

Share to Molecular Targeted Therapy

Share to Neoplasms, Unknown Primary

Share to Oligonucleotide Array Sequence Analysis

Source

Identifiers

PMID: 24037760
DOI: 10.1002/path.4251

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.PMID 24037760Read ↗

Cancer of unknown primary.Semantic proximity Read ↗

Whole genome sequencing improves tissue of origin diagnosis and treatment options for cancer of unknown primarySemantic proximity Read ↗

Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primarySemantic proximity Read ↗

Real-world data analysis of patients with cancer of unknown primarySemantic proximity Read ↗

Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report.Semantic proximity Read ↗

Molecular driver alterations and their clinical relevance in cancer of unknown primary site.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.Semantic proximity Read ↗

Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patientsSemantic proximity Read ↗

A machine learning framework to trace tumor tissue-of-origin of 13 types of cancer based on DNA somatic mutation.Semantic proximity Read ↗

Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patientsSemantic proximity Read ↗

Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.